"Designing Growth Strategies is in our DNA"

Degenerative Disc Disease – Pipeline Review, 2019

Region : Global | Report ID: FBI101284

 

KEY MARKET INSIGHTS

Degenerative disc disease also sometimes known as spondylosis, is associated with an age-related condition that when one or more of the discs between the vertebrae of the spinal column breaks down, causing pain. Other factors that lead to degenerative disc diseases are traumatic injuries that can lead to weakening and swelling of the disc, loss of fluids in the disc due that gradually occurs due to aging, and sport & daily activities can cause the tears in the outer core of the disc. According to the reports published in National Center for Biotechnology Information (NCBI) it was estimated that around 266 million individuals (3.63%) worldwide suffer from Lumbar degenerative spine disease (DSD) with lower back pain every year. Neurological & physical examination and computerized tomography (CT) scan or a magnetic resonance imaging (MRI) methods are used for the diagnosis of degenerative disc disease.


Treatment for degenerative disc disease varies from conservative therapies to surgical interventions aimed to relieve pain, maintain the normal function of the disc, and reduce the stress on the discs. Muscle relaxants, antidepressants, non-steroidal anti-inflammatory drugs, corticosteroids injections, and pain reliever are some of the medications involved in the treatment of degenerative disc disease. Non-surgical treatment methods involve transcutaneous electrical nerve stimulation (TENS) and ultrasound therapy. Discectomy & fusion, corpectomy, facetectomy, laminotomy, and spinal laminectomy are some of the surgical methods used for the treatment of degenerative disc disease. Additionally, physical therapy, massage therapy, and acupuncture are the methods that can aid in relieving the pain associated with degenerative disc disease.


Pharmaceutical companies, along with various research funded organizations, have been focusing on studying and developing new treatment options for degenerative disc disease. For instance; AMG0103, which is being studied by AnGes, Inc., is currently in phase-1 clinical trials used for the study of safety, tolerability and exploratory efficacy of targeted single injection of AMG0103 in subject with chronic discogenic lumbar back pain

To know how our report can help streamline your business, Speak to Analyst


At present, around 79% of the pipeline candidates for degenerative disc disease are in the phase-1, phase-2, and phase-3 stage.


Report Description


The report on ‘Degenerative Disc Disease – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for degenerative disc disease. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for degenerative disc disease.


The report on ‘Degenerative Disc Disease – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.


Report Scope



  • A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target

  • Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration

  • Overview of dormant and discontinued pipeline products

  • Key insights about the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products

  • Overview of the latest developments; news articles, press releases, and relevant conferences


Report Methodology



  • All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.

  • Desk research sourcesinclude global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases


Reasons to Buy this Report



  • Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products fordegenerative disc disease

  • Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players

  • Identify the focus of leading players about R&D for Degenerative disc disease

  • Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business

  • Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary


Degenerative Disc Disease Pipeline Review

    CHOOSE LICENSE TYPE

  • 2050
    4150
    6150

Healthcare Clients

Jubilant
Ipsos
iqvia
Pfizer
Ansell

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X